491 related articles for article (PubMed ID: 26108169)
1. Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.
Hernandez Torres C; Mazzarello S; Ng T; Dranitsaris G; Hutton B; Smith S; Munro A; Jacobs C; Clemons M
Support Care Cancer; 2015 Nov; 23(11):3341-59. PubMed ID: 26108169
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
3. Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.
Ng T; Mazzarello S; Wang Z; Hutton B; Dranitsaris G; Vandermeer L; Smith S; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(2):337-44. PubMed ID: 26732944
[TBL] [Abstract][Full Text] [Related]
4. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
6. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
7. Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making.
Hutton B; Clemons M; Mazzarello S; Kuchuk I; Skidmore B; Ng T
Cancer Treat Rev; 2015 Dec; 41(10):951-9. PubMed ID: 26442474
[TBL] [Abstract][Full Text] [Related]
8. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
[TBL] [Abstract][Full Text] [Related]
9. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
[TBL] [Abstract][Full Text] [Related]
10. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
11. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience.
Al-Salloum HF; Al-Harbi HE; Abdelazeem A
J Oncol Pharm Pract; 2023 Sep; 29(6):1317-1325. PubMed ID: 36518002
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
16. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
19. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial.
Panahi Y; Saadat A; Sahebkar A; Hashemian F; Taghikhani M; Abolhasani E
Integr Cancer Ther; 2012 Sep; 11(3):204-11. PubMed ID: 22313739
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]